David Pook

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

James L. Gulley, Michael Borre, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +17